Eli Lilly Market Cap: How Big It Is and How It Got There

Eli Lilly became the first pharmaceutical company in the world to reach a $1 trillion market value on Friday, November 21, 2025 ^[1]. On that day, shares traded near $1,051, up almost 1%, after briefly touching a record high ^[1]. The stock had rallied more than 35% during 2025, largely on demand for its weight-loss and diabetes drugs ^[1]. As of September 2026, Lilly’s market cap stood at about $1.015 trillion, ranking it the 15th most valuable company in the world by that measure ^[5]. Lilly trades on the New York Stock Exchange under the ticker LLY ^[1][6].

The trillion-dollar mark was reached intraday on a single day, and it is not a fixed level. On September 14, 2026, two sources disagreed on the same-day figure: Nasdaq reported $1.071 trillion while CompaniesMarketCap reported $1.015 trillion ^[5]. CompaniesMarketCap listed the share price at $1,138, up 52.14% over one year ^[5]. Lilly also trades at one of the richest valuations in big pharma, at about 50 times its anticipated earnings over the next 12 months, according to LSEG data ^[1].

How has Lilly’s market cap and revenue grown year by year?

Lilly’s market cap has grown roughly twelvefold since 2016, while its revenue has more than tripled. The table below combines year-end market cap figures from CompaniesMarketCap ^[5] with annual revenue figures from the same third-party compilation ^[4]. These are not audited company filings, and the pre-2021 revenue figures in particular should be treated as approximate ^[4][5].

Year	Market cap (year-end)	Change	Revenue	Change
2016	$81.19B	—	$21.22B	—
2017	$92.99B	+14.5%	$22.87B	+7.8%
2018	$122.38B	+31.6%	$22.29B	−2.5%
2019	$125.84B	+2.8%	$22.31B	+0.1%
2020	$161.50B	+28.3%	$24.53B	+10.0%
2021	$264.22B	+63.6%	$28.31B	+15.4%
2022	$347.61B	+31.6%	$28.54B	+0.8%
2023	$553.36B	+59.2%	$34.12B	+19.6%
2024	$704.31B	+27.3%	$45.04B	+32.0%
2025	$966.15B	+37.2%	$65.17B	+44.7%

Market cap figures are from CompaniesMarketCap ^[5]; revenue figures are from the same site’s revenue compilation ^[4]. Lilly’s trailing-twelve-month revenue as of 2026 was $72.24 billion ^[4].

One year stands out: in 2022, revenue was essentially flat, up just 0.79%, while the year-end market cap rose 31.56% ^[4][5]. Neither source explains the divergence.

What was Eli Lilly before the obesity drug era?

Lilly was founded in Indianapolis in 1876 by Eli Lilly, and the company counts about 150 years of history on its own timeline ^[2][4]. Its early milestones include Iletin in 1923, the world’s first commercially available insulin product, and Prozac (fluoxetine), introduced in Belgium in 1986 as a treatment for clinical depression ^[2].

The Prozac era ended abruptly. On August 9, 2000, a federal appeals court invalidated patent protection for the blockbuster antidepressant, sending Lilly shares down $31 in a matter of hours ^[3]. The day before, the stock had hit an all-time high of $108 ^[3]. The ruling was one of many setbacks that sent the shares on a prolonged slide, and the stock bottomed at $29 during the 2008 financial crisis ^[3]. Lilly’s revenue in 2000 was $10.86 billion, per CompaniesMarketCap’s third-party compilation ^[4].

The 2000s and early 2010s brought a wave of patent expirations. Four blockbusters—the cancer drug Gemzar, the schizophrenia treatment Zyprexa, the antidepressant Cymbalta, and the osteoporosis medicine Evista—were set to lose patent protection through 2014. Together they had generated $10.4 billion of Lilly’s $21.8 billion in 2009 sales ^[3]. Lilly’s total sales topped out at $23.3 billion in 2011 and slipped to a seven-year low of $19.6 billion in 2014 ^[3]. CompaniesMarketCap’s third-party compilation, which should be treated as approximate, shows a similar fall, from $24.28 billion in 2011 to $19.61 billion in 2014 ^[4]. J.P. Morgan forecast at the time that sales would inch up in the year ahead and reach $25.6 billion in 2020 ^[3].

In 2010, Standard & Poor’s analyst Herman Saftlas told Reuters that Lilly had to act or “the patent cliff will kill them” ^[3]. Many analysts questioned whether the company could stay independent without a merger partner. CEO John Lechleiter cut costs, kept the dividend at 49 cents per quarter, and maintained R&D spending rather than shrinking the pipeline ^[3]. Lilly’s largest acquisition to that date came in 2019, when it purchased Loxo Oncology to broaden its cancer treatment options ^[2].

How did tirzepatide turn Lilly into the world’s most valuable drugmaker?

The turn came with tirzepatide. Lilly introduced Mounjaro (tirzepatide) for type 2 diabetes in 2022, and Zepbound (tirzepatide) was approved for chronic weight management in 2023 ^[2]. Sales of tirzepatide have since surpassed Merck’s Keytruda as the world’s best-selling drug ^[1].

Novo Nordisk had the early lead in obesity treatment, but its Wegovy launch in 2021 was hampered by supply shortages, which gave Lilly room to gain ground ^[1]. Reuters reported that Lilly’s drugs have shown stronger clinical efficacy, and that the company has been faster to scale up manufacturing and expand distribution ^[1]. Since Zepbound’s launch in late 2023, Lilly shares have gained more than 75%, compared with a rise of over 50% in the S&P 500 over the same period ^[1].

Wall Street estimates the weight-loss drug market will be worth $150 billion by 2030, with Lilly and Novo Nordisk together controlling the majority of projected global sales ^[1].

What were Lilly’s 2025 full-year results?

Lilly’s full-year 2025 revenue was $65,179 million, up 45% from $45,043 million in 2024 ^[6]. The two tirzepatide brands drove most of it: Mounjaro brought in $22,965 million, up 99%, and Zepbound brought in $13,542 million, up 175% ^[6]. Verzenio, a breast cancer drug, added $5,723 million, up 8% ^[6].

In the fourth quarter of 2025, revenue was $19,292 million, up 43%, with volume up 46% and realized prices down 5% ^[6]. Reported earnings per share were $7.39, up 51%, and non-GAAP EPS was $7.54, up 42%; both included $0.52 of acquired IPR&D charges ^[6]. Research and development spending was $3.8 billion, up 26%, or 20% of revenue ^[6].

With those results, issued February 4, 2026, Lilly gave initial 2026 guidance of $80 billion to $83 billion in revenue and non-GAAP EPS of $33.50 to $35.00 ^[6].

How is 2026 going so far?

Lilly raised its full-year outlook after a strong first half. Second-quarter 2026 revenue was $22,974 million, up 48% from $15,558 million in Q2 2025 ^[7]. First-half revenue was $42,773 million, up 51%; that implies about $19.8 billion in Q1 2026 ($42,773 million minus $22,974 million), versus roughly $12.7 billion in Q1 2025 ^[7].

Mounjaro generated $9,943 million in Q2 2026, up 91%, and Zepbound generated $4,928 million, up 46% worldwide and 44% in the U.S. ^[7]. Reported EPS was $7.94, up 26%, and non-GAAP EPS was $8.38, up 33%; both included $3.03 of acquired IPR&D charges, compared with $0.14 a year earlier ^[7].

On August 5, 2026, Lilly raised full-year 2026 guidance to revenue of $85.0 billion to $87.0 billion and non-GAAP EPS of $35.50 to $36.50 ^[7]. The underlying non-GAAP EPS guidance was raised by $2.78 at the midpoint, which was more than offset by the $3.03 of acquired IPR&D charges from second-quarter business development ^[7].

Other products in Q2 2026 included Jaypirca at $192 million, Ebglyss at $201 million, Kisunla at $167 million, Omvoh at $102 million, Inluriyo at $75 million, and Foundayo at $98 million in its first reported quarter ^[7].

Is Lilly’s growth coming from price increases?

No. Lilly’s growth is coming from volume, and prices are falling. In Q2 2026, worldwide volume rose 60% while realized prices fell 13% ^[7]. Outside the U.S., revenue rose 80% to $8.6 billion on volume growth of 113%, partially offset by a 36% decline in realized prices, driven mainly by Mounjaro’s addition to China’s National Reimbursement Drug List in Q1 2026 ^[7].

In the U.S., Q2 2026 revenue rose 33% to $14.4 billion, with volume up 37% and realized prices down 3%—about 9% excluding adjustments to rebate and discount estimates ^[7]. Zepbound’s U.S. price decline includes previously announced reductions in cash-pay prices ^[7]. The pattern held in Q4 2025 as well, when U.S. volume rose 50% and realized prices fell 7% ^[6].

Who owns Eli Lilly?

Lilly is a publicly traded company, but one shareholder stands out. Lilly Endowment, Inc., an Indiana not-for-profit classified as a private foundation under Section 501(c)(3) and Section 509(a), beneficially owned 90,376,978 shares as of June 30, 2026—9.6% of Lilly’s common stock ^[8]. That percentage is based on 941,741,406 shares outstanding as of April 27, 2026, as reported in Lilly’s Form 10-Q for the period ended March 31, 2026 ^[8].

The Endowment has sole voting power and sole dispositive power over all 90,376,978 shares, with no shared power, and it filed as a passive investor on Schedule 13G/A ^[8]. The Endowment was established in 1937 by Lilly family members to pursue personal philanthropy ^[2]. Pensions & Investments has flagged the concentration risk of an endowment portfolio that is roughly 97% a single stock, though the article text itself was not retrievable ^[9].

How much of Lilly’s revenue depends on Mounjaro and Zepbound?

More than half, and the share is growing. Mounjaro and Zepbound together generated $36,507 million of Lilly’s $65,179 million in full-year 2025 revenue, about 56% ^[6]. In Q2 2026, the two brands produced $14,871 million of $22,974 million in total revenue, about 65% ^[7]. In the quarter Reuters reported around the trillion-dollar milestone, the obesity and diabetes portfolio brought in more than $10.09 billion of $17.6 billion in total revenue, again more than half ^[1].

Analysts are watching whether that growth holds as Mounjaro and Zepbound prices come under pressure and margins face a squeeze ^[1]. The contrast with the last decade is notable: the 2011-era patent cliff was spread across four separate blockbusters worth $10.4 billion of $21.8 billion in 2009 sales ^[3]. Today’s concentration sits in two brands of the same molecule.

What is Lilly doing to diversify?

Lilly is spending heavily on acquisitions, pipeline, and manufacturing. In Q2 2026, it completed the acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics ^[7]. After the quarter ended, it completed three acquisitions forming an infectious disease portfolio and entered an agreement to acquire AtaiBeckley ^[7]. The Q2 2026 acquired IPR&D charges totaled $2.8 billion, versus $154 million in Q2 2025, along with $703 million of impairment and restructuring charges tied to the Kelonia and Centessa closings ^[7].

The pipeline is also advancing. Retatrutide’s clinical data package is complete for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with a U.S. Biologics License Application planned for the first quarter of 2027 ^[7]. Orforglipron, an oral GLP-1, has been submitted for obesity in the U.S., Japan, and the EU, with a U.S. type 2 diabetes submission in Q2 2026 ^[6][7]. Reuters reported in November 2025 that orforglipron was expected to be approved early the following year ^[1]. Lilly has also committed an additional $4.5 billion to expand its Indiana manufacturing sites, announced with Q2 2026 results ^[7].

Lilly also reached an agreement with the U.S. government to expand access to obesity medicines. Analysts estimate the deal could add as many as 40 million potential U.S. candidates for obesity treatment, though it may weigh on near-term revenue ^[1][6].

What should investors watch next?

The open questions are the durability of the metabolic franchise, the orforglipron launch, pricing pressure, and whether pipeline progress and dealmaking can offset a potential margin squeeze ^[1]. Evan Seigerman, an analyst at BMO Capital Markets, said the valuation points to investor confidence in the long-term durability of the metabolic health franchise and suggests investors prefer Lilly over Novo in the obesity race ^[1]. James Shin, director of biopharma equity research at Deutsche Bank, said Lilly is starting to resemble the “Magnificent Seven” tech heavyweights again ^[1].

In October 2025, Lilly raised its annual revenue forecast by more than $2 billion at the midpoint on surging global demand for its obesity and diabetes drugs ^[1].

Sources

1. Reuters. Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand. November 21, 2025.
2. Eli Lilly and Company. History: milestones of caring and discovery.
3. Indianapolis Business Journal. How Eli Lilly CEO Lechleiter pulled company out of long slide.
4. CompaniesMarketCap. Eli Lilly (LLY) revenue.
5. CompaniesMarketCap. Eli Lilly (LLY) market capitalization.
6. PR Newswire. Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance.
7. PR Newswire. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress.
8. StockTitan. Lilly Endowment holds 9.6% stake in Eli Lilly. SEC Form Schedule 13G/A.
9. Pensions & Investments. Lilly Endowment tops $100 billion as Eli Lilly stock surges.
10. Fierce Pharma. Lilly rewards CEO David Ricks with $36.7M pay package for 2025, fueled by GLP-1 success. March 9, 2026.
11. Eli Lilly and Company. Definitive proxy statement (DEF 14A), filed March 17, 2026.
12. Indiana Business Research Center, Kelley School of Business, Indiana University. Eli Lilly and Company’s impact: measuring Lilly’s economic and civic contributions in Indiana. May 2026.
13. Axios Indianapolis. Eli Lilly celebrates 150 years on precipice of new era. May 13, 2026.
14. Eli Lilly and Company. Annual report on Form 10-K for fiscal year ended December 31, 2025.
15. Eli Lilly and Company. Key facts.
16. US Securities and Exchange Commission. Eli Lilly and Company Form 8-K current report. May 7, 2026.